Ophthotech’s wet-AMD drug Fovista fails in phase 3 AMD trial
The trial dubbed as OPH1004 had investigated the superiority of Fovista in combination with Eylea (aflibercept) or Avastin (bevacizumab) anti-VEGF therapy over Eylea or Avastin monotherapy. It was
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.